Ojer Pharma — Seed · €600K

Inveready Innvierte Biotech II joined as a shareholder by closing a €600,000 round, with existing shareholders Sodena and Clave Mayor's funds taking part. The money goes to finishing development and starting European sales of Lipovir® and Impetine®.

LeadInveready RoundSeed Announced18 Jul 2014 CityPamplona SectorHealthtech & Bio · Biotech / Dermatology pharma Source C

Something wrong? Suggest a correction →